特发性矮小症和生长激素缺乏症应用重组人生长激素的临床效果观察  

Clinical Effect of Recombinant Human Growth Hormone in Patients with Idiopathic Short Stature and Growth Hormone Deficiency

作　　者：蒋苇苇 高莉莉 陈风展[1] JIANG Weiwei;GAO Lili;CHEN Fengzhan(Taizhou Second People’s Hospital,Taizhou 225500,China;不详)

机构地区：[1]江苏省泰州市第二人民医院,江苏泰州225500 [2]徐州医科大学附属医院

出　　处：《中国医学创新》2021年第1期114-117,共4页Medical Innovation of China

摘　　要：目的:观察与分析特发性矮小症和生长激素缺乏症应用重组人生长激素的临床效果。方法:选取2016年3月-2018年3月本院收治的80例特发性矮小症和生长激素缺乏症患者为研究对象。将其随机分为对照组(常规治疗干预组)和观察组(常规治疗加重组人生长激素组),每组40例。比较两组治疗前后身高、身高SDS、生长速率、血清生长因子及骨代谢相关指标,观察两组不良反应发生情况。结果:治疗前,两组的身高、身高SDS、生长速率、血清生长因子、血清骨代谢相关指标比较,差异均无统计学意义(P>0.05)。治疗3、6、12个月后,观察组身高、身高SDS、生长速率、血清生长因子、血清骨代谢相关指标均显著优于对照组,差异均有统计学意义(P<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:特发性矮小症和生长激素缺乏症应用重组人生长激素的临床效果较好,安全性值得肯定,因此在特发性矮小症和生长激素缺乏症患者中的应用价值较高。Objective:To observe and analyze the clinical effect of Recombinant Human Growth Hormone in the patients with idiopathic short stature and growth hormone deficiency.Method:A total of 80 patients with idiopathic short stature and growth hormone deficiency admitted to our hospital from March 2016 to March 2018 were selected as the research objects.They were randomly divided into control group(routine treatment intervention group)and observation group(routine treatment plus Recombinant Human Growth Hormone group),40 cases in each group.Height,height SDS,growth rate,serum growth factor and bone metabolism were compared between two groups before and after treatment,the occurrence of adverse reactions in the two groups was observed.Result:Before treatment,there were no statistically significant differences in height,height SDS,growth rate,serum growth factor and serum bone metabolism between two groups(P>0.05).At 3,6 and 12 months after treatment,the height,height SDS,growth rate,serum growth factor and serum bone metabolism related indexes of the observation group were all significantly better than those of the control group,with statistically significant differences(P<0.05).There was no statistically significant difference in the incidence of adverse reactions between two groups(P>0.05).Conclusion:The clinical effect of Recombinant Human Growth Hormone on idiopathic short stature and growth hormone deficiency is good,and its safety is worthy of affirmation.Therefore,it has high application value in patients with idiopathic short stature and growth hormone deficiency.

关 键 词：特发性矮小症 生长激素缺乏症 重组人生长激素 

分 类 号：R725.8[医药卫生—儿科]